Skin Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Merkel Cell Carcinoma (21)

Squamous Cell Skin Cancer (20)

Basal Cell Carcinoma (17)

Merkel Cell Carcinoma (21)

Squamous Cell Skin Cancer (20)

Basal Cell Carcinoma (17)

›

PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	nivolumab/relatlimab Sensitive: A1 - Approval N Engl J Med - 3 weeks (New B) nivolumab / relatlimab Sensitive : A1 N Engl J Med - 3wk	nivolumab/relatlimab Sensitive: A1 - Approval N Engl J Med - 3 weeks nivolumab / relatlimab Sensitive : A1 N Engl J Med - 3 weeks - (New B)
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	fluorouracil topical Sensitive: A1 - Approval fluorouracil topical Sensitive : A1	fluorouracil topical Sensitive: A1 - Approval fluorouracil topical Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	vismodegib Sensitive: A1 - Approval vismodegib Sensitive : A1	vismodegib Sensitive: A1 - Approval vismodegib Sensitive : A1
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	imiquimod Sensitive: A1 - Approval imiquimod Sensitive : A1	imiquimod Sensitive: A1 - Approval imiquimod Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	trametinib Resistant: A1 - Approval trametinib Resistant : A1	trametinib Resistant: A1 - Approval trametinib Resistant : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	sonidegib Sensitive: A1 - Approval sonidegib Sensitive : A1	sonidegib Sensitive: A1 - Approval sonidegib Sensitive : A1
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1

Skin Cancer

Associations(986)

Associations
(986)